This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Fludroxycortide topical


Topical formulations of fludroxycortide.

Drugs List

  • fludroxycortide 0.0125% cream
  • Therapeutic Indications





    1 application one to three times a day, for moist weeping lesions.


    1 application one to three times a day, for moist weeping lesions.

    Courses should be limited to five days and occlusion should not be used.

    Additional Dosage Information

    Dilution is not recommended. If it is considered necessary aqueous cream may be used.

    Several minutes should elapse between application of topical corticosteroids and emollients.


    Children under 1 year
    Acne vulgaris
    Genital pruritus
    Perianal pruritus
    Perioral dermatitis
    Skin manifestation of tuberculosis

    Precautions and Warnings


    Careful supervision of patients with psoriasis required
    Contains cetyl alcohol - may cause local skin reactions
    Contains propylene glycol: may cause irritation
    Application under occlusion should be restricted to limited areas
    Avoid contact with eyes
    Avoid occlusion in children or on face
    May cause local and systemic toxicity especially in prolonged/extensive use
    May cause local and systemic toxicity especially with polythene occlusion
    Prolonged or high dose may lead to adrenal suppression
    Corticosteroids may cause growth retardation in children under 18 years
    Potential for withdrawal symptoms
    Risk of generalised pustular psoriasis with use of topical corticosteroids
    Discontinue therapy and use antimicrobials if secondary infection occurs
    Avoid long term continuous therapy
    Limit use in children to 5 days
    Limit use on face to 5 days
    Advise patient residue on clothing/bedding may cause fire hazard
    Fire hazard: Keep away from naked flames and potential sources of ignition

    Systemic absorption of fludroxycortide has resulted in reversible HPA axis suppression. If a large dose is being applied over a large area or an occlusive dressing is being used periodic urinary free cortisol and ACTH stimulation tests should be carried out. If HPA axis suppression is observed the treatment should either be withdrawn, possibly being replaced by a less potent steroid, or a reduction of the frequency of application. On discontinuation recovery is fast and complete, but some steroid withdrawal symptoms may occur requiring a supplemental systemic corticosteroid to be administered.

    Children may absorb proportionally larger amounts of topical corticosteroids and thus may be more susceptible to systemic toxicity. Children may also demonstrate greater susceptibility to topical corticosteroid induced HPA axis suppression and Cushing's Syndrome because a larger skin surface to body weight ratio.

    Antifungal or antibacterial agents should be co-administered in the presence of infection. If a favourable response does not occur promptly, the administration of fludroxycortide should be withdrawn until the infection has been adequately controlled.

    The use of an occlusive dressing can enhance the effects of fludroxycortide. Fludroxycortide should not be used as a substitute for preparations used in the conventional management of skin lesions. It should be used as a supplement to lotions and wet dressings.

    Rarely, severe skin reactions and adverse effects may occur on stopping treatment with topical corticosteroids. Consider the lowest potency required and counsel patient on safe and effective use.

    Patients or carers should be advised on application of fludroxycortide cream.

    Patients or carers should seek medical advice before using a topical corticosteroid on a new body area, as some areas of the body are more prone to side effects.

    Pregnancy and Lactation


    Use fludroxycortide with caution during pregnancy.

    The manufacturer recommends that fludroxycortide is only used during pregnancy when there is no safer alternative and when the disease itself carries risks for the mother and child.

    At the time of writing there is limited published information regarding the topical use of fludroxycortide during pregnancy; however, animal studies have shown evidence of harmful effects. There may be a very small risk of cleft palate and intra-uterine growth retardation and suppression of the neonatal HPA axis.


    Use fludroxycortide with caution during breastfeeding.

    The manufacturer recommends that caution should be exercised when fludroxycortide is administered to breastfeeding mothers.

    At the time of writing there is limited published information regarding the topical use of fludroxycortide during breastfeeding. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into the breast milk, but in small quantities that are unlikely to cause harm to the infant.

    Side Effects

    Acne (at application site)
    Allergic contact dermatitis
    Bulging fontanelles in infants
    Cushing's syndrome
    Dry skin
    Growth retardation (children)
    Hypersensitivity reactions
    Intracranial hypertension
    Irritation (localised)
    Local burning
    Maceration of skin
    Mild depigmentation and vellus hair
    Perioral dermatitis
    Reduction in serum cortisol levels
    Secondary infections
    Skin atrophy
    Suppression of the hypothalamic-pituitary-adrenal axis
    Systemic steroid effects
    Weight gain
    Wound healing retarded


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2022

    Reference Sources

    Summary of Product Characteristics: Fludroxycortide 0.0125% w/w Cream. Typharm Ltd. Revised August 2021.

    MHRA Drug Safety Update September 2021 Available at:
    Last accessed: 10 August 2022

    NICE Evidence Services Available at: Last accessed: 10 August 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.